Sinsin Pharmaceutical Co., Ltd (KOSDAQ:002800)
South Korea flag South Korea · Delayed Price · Currency is KRW
4,380.00
+10.00 (0.23%)
At close: Aug 24, 2026

Sinsin Pharmaceutical Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
11,1519,2924,8884,6804,415-1,476
Depreciation & Amortization
4,0714,1524,2603,9373,7583,672
Loss (Gain) From Sale of Assets
-14.26-36.35-70-38.55-0.73
Asset Writedown & Restructuring Costs
-----18.16
Loss (Gain) From Sale of Investments
-138.96-138.96323.41---
Provision & Write-off of Bad Debts
45.396.23143.72-30.85-159.251.26
Other Operating Activities
3,7273,2941,9952,3661,531-344.75
Change in Accounts Receivable
-3,273-2,202-2,597-2,201-2,373-659.54
Change in Inventory
-4,896-5,424-2,302-3,022-5,0621,316
Change in Accounts Payable
1,081-1,465195.72241.532,063-2,165
Change in Other Net Operating Assets
403.681,106-956.49-2,0421,327-337.92
Operating Cash Flow
12,1578,5845,9433,9305,46123.18
Operating Cash Flow Growth
108.71%44.42%51.23%-28.03%23453.48%-98.76%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-2,046-1,612-1,505-5,011-907.13-2,682
Sale of Property, Plant & Equipment
14.636.77-43.640.79
Sale (Purchase) of Intangibles
---10-16.11-94.65-
Investment in Securities
-228.42-126.39-4,004-1,004-176.61-3.41
Other Investing Activities
-596.66-603.38-46-20-1033
Investing Cash Flow
-2,856-2,305-5,557-6,051-1,145-2,652

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
-38,84739,88825,30618,34920,224
Long-Term Debt Issued
-----3,000
Total Debt Issued
52,89738,84739,88825,30618,34923,224
Short-Term Debt Repaid
--39,165-35,397-20,958-19,275-17,421
Long-Term Debt Repaid
--1,685-3,790-3,434-1,899-4,914
Total Debt Repaid
-57,857-40,850-39,187-24,392-21,174-22,335
Net Debt Issued (Repaid)
-4,960-2,003701.82914.06-2,825889.86
Dividends Paid
-910.23-910.23-910.23-758.53--
Other Financing Activities
1515-70-35
Financing Cash Flow
-5,855-2,898-208.41225.54-2,825924.86

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
-30.95-43.1215.791.89-50.12-0.96
Miscellaneous Cash Flow Adjustments
-0-0-00-0-
Net Cash Flow
3,4153,337193.4-1,8941,441-1,705

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
10,1116,9714,439-1,0814,553-2,659
Free Cash Flow Growth
121.53%57.05%----
Free Cash Flow Margin
8.52%6.13%4.17%-1.05%4.95%-3.59%
Free Cash Flow Per Share
667.13459.53292.38-71.27300.15-175.28
Levered Free Cash Flow
6,8764,1701,950-3,1573,362-2,642
Unlevered Free Cash Flow
7,8325,1933,175-1,9464,288-2,040

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
1,5211,6311,9561,9871,406948.55
Cash Income Tax Paid
433.54317.41182.18-747.52-396.261,650
Change in Working Capital
-6,684-7,986-5,660-7,023-4,045-1,846